The DOI matches its Crossref record; 58 of the 62 references it cites were found in a registry or an index.
Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma
Open accessPublished version of a preprint
Abstract
Although anti–PD-1 therapy has improved clinical outcomes for select patients with advanced cancer, many patients exhibit either primary or adaptive resistance to checkpoint inhibitor immunotherapy. The role of the tumor stroma in the development of these mechanisms of resistance to checkpoint inhibitors remains unclear. We demonstrated that pharmacologic inhibition of the TGFβ signaling pathway synergistically enhanced the efficacy of anti–CTLA-4 immunotherapy but failed to augment anti–PD-1/PD-L1 responses in an autochthonous model of BRAFV600E melanoma. Additional mechanistic studies revealed that TGFβ pathway inhibition promoted the proliferative expansion of stromal fibroblasts, thereby facilitating MMP-9–dependent cleavage of PD-L1 surface expression, leading to anti–PD-1 resistance in this model. Further work demonstrated that melanomas escaping anti–PD-1 therapy exhibited a mesenchymal phenotype associated with enhanced TGFβ signaling activity. Delayed TGFβ inhibitor therapy, following anti–PD-1 escape, better served to control further disease progression and was superior to a continuous combination of anti–PD-1 and TGFβ inhibition. This work illustrates that formulating immunotherapy combination regimens to enhance the efficacy of checkpoint blockade requires an in-depth understanding of the impact of these agents on the tumor microenvironment. These data indicated that stromal fibroblast MMP-9 may desensitize tumors to anti–PD-1 and suggests that TGFβ inhibition may generate greater immunologic efficacy when administered following the development of acquired anti–PD-1 resistance. See related Spotlight on p. 1444
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source doesn’t support the claim as written.
In the citing paper
“PD-L1 downregulation by melanoma in vivo , in the context of delayed TGF b inhibition”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Zhao et al., 2018
Checked by a reasoning model — may be wrong.
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“upfront TGFb inhibition appears to promote at least some degree of resistance to PD1 blockers by favoring matrix metallopeptidase 9 (MMP9)driven PD-L1 cleavage”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Zhao et al., 2018
In the citing paper
“Conversely, however, pharmacological inhibition of the TβRI kinase enhances stromal fibroblast proliferation in a mouse melanoma model38.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [38]
In the citing paper
“Recent results in fact highlight the role of increased TGF-β signaling in intrinsic resistance to checkpoint blockade therapy21,23,38,71,145.”
From TGFβ biology in cancer progression and immunotherapy (2021) · cites this paper as [38]
In the citing paper
“the administration of TGFb inhibitors once acquired PD-1 resistance has emerged mediates robust therapeutic effects”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Zhao et al., 2018
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628 · cited 1×
“Despite these additions to our treatment armamentarium, most advanced cancer patients remain resistant to checkpoint inhibitor therapies (3).”
BackgroundMootha, V. K., Lindgren, C. M., Eriksson, K.-F., Subramanian, A., Sihag, S., Lehar, J., Puigserver, P., Carlsson, E., Ridderstråle, M., Laurila, E., et al. (2003) · Nature Genetics · doi:10.1038/ng1180 · Cited by 10,197 · cited 1×
“Gene set enrichment analysis was performed to identify differentially regulated pathways and gene ontology terms for each of the comparisons performed (25).”
MethodPrimary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Sharma, P., Hu-Lieskovan, S., Wargo, J. A., & Ribas, A. (2017) · Cell · doi:10.1016/j.cell.2017.01.017 · Cited by 5,588
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 1×
“These data are consistentwith reported findings supporting a role for stromal fibroblast TGFb signaling and T-cell exclusion in certain solid tumors (35, 36).”
ResultDissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
Tirosh, I., Izar, B., Prakadan, S. M., Wadsworth, M. H., Treacy, D., Trombetta, J. J., Rotem, A., Rodman, C., Lian, C., Murphy, G., et al. (2016) · Science · doi:10.1126/science.aad0501 · Cited by 4,944 · cited 1×
“Melanoma-associated fibroblasts (MAF) have also been demonstrated to play an important role in the induction of immune suppression via melanoma–stroma cross-talk and RNA-seq studies have related TAF abundance with targeted drug resistance, as well as checkpoint inhibitor resistance in advanced melanoma (21, 22).”
BackgroundGenomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Hugo, W., Zaretsky, J. M., Sun, L., Song, C., Moreno, B. H., Hu-Lieskovan, S., Berent-Maoz, B., Pang, J., Chmielowski, B., Cherry, G., et al. (2016) · Cell · doi:10.1016/j.cell.2016.02.065 · Cited by 3,448 · cited 5×
“Melanoma-associated fibroblasts (MAF) have also been demonstrated to play an important role in the induction of immune suppression via melanoma–stroma cross-talk and RNA-seq studies have related TAF abundance with targeted drug resistance, as well as checkpoint inhibitor resistance in advanced melanoma (21, 22).”
BackgroundMethodResultInfluentialMatrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis
Bergers, G., Brekken, R., McMahon, G., Vu, T. H., Itoh, T., Tamaki, K., Tanzawa, K., Thorpe, P., Itohara, S., Werb, Z., et al. (2000) · Nature Cell Biology · doi:10.1038/35036374 · Cited by 2,797
Topalian, S. L., Sznol, M., McDermott, D. F., Kluger, H. M., Carvajal, R. D., Sharfman, W. H., Brahmer, J. R., Lawrence, D. P., Atkins, M. B., Powderly, J. D., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.0105 · Cited by 2,222
Prognostic and predictive factors in breast cancer by immunohistochemical analysis.
Allred, D. C., Harvey, J. M., Berardo, M. D., & Gm, C. (1998) · PubMed · Cited by 2,143
Research works printed but not linked: 1
- Hanks, 2013, Type III TGF-beta receptor downregulation generates an immunotolerant tumor microenvironment, J Clin Invest, 123, 3925, 10.1172/JCI65745 · DOI
Cited by
TGFβ biology in cancer progression and immunotherapy
Derynck, R., Turley, S. J., & Akhurst, R. J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0403-1 · Cited by 944
Single-cell analysis reveals fibroblast clusters linked to immunotherapy resistance in cancer.
Kieffer, Y., Hocine, H. R., Gentric, G., Pelon, F., Bernard, C., Bourachot, B., Lameiras, S., Albergante, L., Bonneau, C., Guyard, A., et al. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-1384 · Cited by 910
Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?
Strickler, J. H., Hanks, B. A., & Khasraw, M. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3054 · Cited by 418
Overcoming TGFβ-mediated immune evasion in cancer
Tauriello, D. V. F., Sancho, E., & Batlle, E. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-021-00413-6 · Cited by 377
Theivanthiran, B., Evans, K. S., DeVito, N. C., Plebanek, M., Sturdivant, M., Wachsmuth, L. P., Salama, A. K. S., Kang, Y., Hsu, D., Balko, J. M., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci133055 · Cited by 248
Metadata
- Authors
- Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A.
- Affiliations
- Duke University (US)
- University of North Carolina at Chapel Hill (US)
- University Hospital Regensburg (DE)
- Corresponding author
- Hanks, Brent A.
- ORCID
- Venue
- Cancer Immunology Research
- Published
- 2018-12-01
- Volume
- 6
- Issue
- 12
- Pages
- 1459-1471
- ISSN
- 2326-6066 (ISSN-L)
- 2326-6074
- PMC
- PMC6279598
- OpenAlex
- W2890611687
- Cited by
- 117
- References
- 62
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 8 · 2023: 7 · 2022: 22 · 2021: 17 · 2020: 23 · 2019: 15 · 2018: 1
- FWCI
- 5.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Cancer Immunology Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- University of Regensburg Publication Server (University of Regensburg) (submittedVersion)
- Funders
- HHS | National Institutes of Health (NIH) (1K08CA191063-01A1)
- Melanoma Research Alliance (MRA) (Young Investigator Award)
- Duke University School of Medicine (Duke Health Scholars Award)
- MedPacto, Inc. (Pre-clinical Research Award)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- anti-PD-1 resistance, tumor stromal fibroblasts, TGF-beta inhibition, MMP-9, melanoma, BRAF V600E mutation, tumor microenvironment, mesenchymal phenotype, immunotherapy resistance, treatment sequencing
- MeSH terms
- Animals, Female, Fibroblasts, Immunotherapy, Male, Melanoma, Mice, Inbred BALB C, Mice, Inbred C57BL, Mice, Transgenic, Pyrazoles, Quinolines, Transforming Growth Factor beta, Drug Resistance, Neoplasm, Matrix Metalloproteinase 9, Xenograft Model Antitumor Assays, Proto-Oncogene Proteins B-raf, Tumor Microenvironment, B7-H1 Antigen, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma. https://app.cochat.ai/papers/10.1158/2326-6066.cir-18-0086
- The paper
- Zhao, F., Evans, K., Xiao, C., DeVito, N., Theivanthiran, B., Holtzhausen, A., Siska, P. J., Blobe, G. C., & Hanks, B. A. (2018). Stromal fibroblasts mediate anti-PD-1 resistance via MMP-9 and dictate TGFβ inhibitor sequencing in melanoma. Cancer Immunology Research. https://doi.org/10.1158/2326-6066.cir-18-0086
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.